cyrilzakka/clinical-trials huggingface dataset:
Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin

Open clinical study to evaluate the soothing activity of a body cream to be applied once a day, mono-laterally at level of the antecubital fold and forearm, for an uninterrupted period of 1 month, by 22 adult volunteers, with positive anamnesis for atopy and habitual itching.


Eligibility Criteria:
Inclusion Criteria:

* Adult volunteers of both sexes
* volunteers with positive anamnesis for atopy and habitual itching
* volunteers in a good general state of health in the Investigator opinion
* negative pregnancy test (only for female subjects not in menopause)
* accepting to follow the instructions received by the investigator
* accepting to not change their habits regarding food, physical activity, body cleansing
* agreeing not to apply or take any product/drug or use body massages able to change skin conditions during the entire duration of the study
* accepting not to expose their face to strong UV irradiation (UV session, or sun bathes), during the entire duration of the study
* no participation in a similar study currently or during the previous 3 months
* volunteers who are giving a written informed consent.

Exclusion Criteria:

* Pregnancy (only for female subjects not in menopause)
* lactation (only for female subjects not in menopause)
* change in the normal habits in the last month
* participation in a similar study during the previous 3 months
* known allergy to one or several ingredients of the product on trial
* insufficient adhesion to the study protocol
* Dermatitis
* presence of cutaneous disease on the tested area, as lesions, scars, malformations
* clinical and significant skin condition on the test area.
* Diabetes
* endocrine disease
* hepatic disorder
* renal disorder
* cardiac disorder
* pulmonary disease
* cancer
* neurological or psychological disease
* inflammatory/immunosuppressive disease
* drug allergy.
* Anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago)
* using of drugs able to influence the test results in the investigator opinion.
Reliability of Elbow Flexion and Extension Strength Measurement Protocols Using a Hand-held Dynamometer

The aim of the study was to investigate the intra-rater and inter-rater reliability of elbow strength measurement procedures performed in different body postures and shoulder and elbow positions using a hand-held dynamometer in healthy individuals and to determine the standard error of measurement (SEM) and minimum detectable change (MDC) values for these procedures.

Healthy university students aged 18 years and older will be included in the study. Elbow flexion and extension strength will be measured in both arms in different body postures and shoulder and elbow positions using a hand-held dynamometer. Thus, the reliability of these procedures will be investigated, and the standard error of the measurement and the minimum detectable change will be determined. Strength measurements will be performed by two physiotherapists on each arm of the participants and repeated between 3 - 7 days after the measurement to evaluate both intra-rater and inter-rater reliability.

3 different positions will be used for elbow flexion:

1. Participants sit on a stool, and their arms are at the side with the elbow flexed 90° (forearm in supination).
2. Participants sit on a stool, and their shoulder and elbow are flexed to 90° (forearm in supination) and supported on the treatment table.
3. Participants lie supine and place their shoulders on neutral position and elbow flexed 90° (forearm in supination).

3 different positions will be used for elbow extension:

1. Participants sit on a stool, and their shoulder and elbow are flexed to 90° (forearm in supination) and supported on the treatment table.
2. Participants lie supine and place their shoulders on neutral position and elbow flexed 90° (forearm in supination).
3. Participants lie prone, and their shoulders аre placed at 90° abduction and elbows flexed to 90°.

Eligibility Criteria:
Inclusion Criteria:

-Being older than 18 years old

Exclusion Criteria:

* Having neck, shoulder, elbow or forearm injuries in the last 6 months,
* Having upper extremity or neck fracture or surgical history
* Symptoms related to the neck, shoulder, elbow, and forearm at the time of assessment
* Having neurological or systemic musculoskeletal diseases or disorders
* Having a diagnosis of chest deformity or scoliosis
* Doing regular exercise related to upper extremity for the last year
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes

Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP\<130/80 mmHg. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP\<130/80 mmHg by treatment groups. To observe the proportion of patients achieving a therapeutic glycemic response defined as HbA1c=\<7%. To observe the proportion of patients achieving fasting plasma glucose\<110 mg%. To identify factors for not achieving BP\<130/80 mmHg. To describe percentage of patients with positive proteinuria (including microalbuminuria) by treatment groups .


Eligibility Criteria:
Inclusion Criteria:

* Provision of written informed consent
* Patient was diagnosed with type 2 diabetes
* Patient is on antihypertensive treatments for at least 3 months, with the same regimen for a minimum of 4 weeks prior to survey

Exclusion Criteria:

* Patients are critically ill, had mental health problems or difficulty in communication
* Patients who are unwilling or unable to provide informed consent
* Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
Perioperative Inflammation and Breast Cancer Outcome

It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent the several cancers. In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory drug) has been suggested.However, there was no consistent results. surgery is main cause of inflammation for cancer patients. Therefore, we want to know the association between prevention of perioperative inflammation with NSAIDS and breast cancer outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Breast cancer patients who took the surgery

Exclusion Criteria:

* underlying medical disease (major heart disease, lung disease, coagulopathy)
* major psychologic disease (major depression, schizophrenia, manic disorder)
* pregnancy
* rheumatic disease patients
r-tPA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke Recovery

to detect the efficiency and safety of intravenous rtPA combined with RIPC in acute ischemic stroke patients

Remote ischemic post-conditioning, which consists of several brief cycles of intermittent ischemia-reperfusion of the arm or leg, may potentially confer a powerful systemic protection against prolonged ischemia in a distant organ. Numerous reports have confirmed it strongest endogenous neuroprotection against brain injury after stroke. Ren et al demonstrated that remote ischemic post-conditioning (RIPC) performed in the hind limbs can not only significantly reduce the stroke volume within 3 hours in rat model, but also ameliorate the outcome of the behavioral test. A long-term repeated RIPC therapy can also help improving neurological functions. A combination of RIPC and tPA can help with neuroprotection which improves the neurological functions. Thus, it is meaningful to transform these basic experimental results to the clinical treatment. In the RECAST-1 trial, RIC has shown it safety and efficiency in AIS patients without tPA. However, there is no further explanation for the patients with IVT. Thus, in this study, we aim to demonstrate the efficiency and safety of RIPC in AIS patients performed rt-PA within 4.5 hours.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, age≥18;
* Clinical sign and symptoms consistent with the diagnosis of an acute ischemic stroke, onset of stroke symptoms within 4.5 h before initiation of intravenous rt-PA thrombolytic therapy;
* Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-15 (assessed before intravenous alteplase), mRS ≤1 before onset of stroke symptom;
* No contraindication for MRI.
* Informed consent obtained

Exclusion Criteria:

* Cardioembolism；
* Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs;
* Life expectancy \< 1 year;
* Pregnant or breast-feeding women;
* Unwilling to be followed up or poor compliance for treatment; (5) Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.
ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis

The purpose of this research study is to demonstrate that individuals with upper limb paralysis due to spinal cord injury, brachial plexus injury, amyotrophic lateral sclerosis and brain stem stroke can successfully achieve direct brain control of assistive devices using an electrocorticography (ECoG)-based brain computer interface system.

Brain-computer interface (BCI) technology aims to establish a direct link for transmitting information between the brain and external devices, offering a natural and rich control signal for prosthetic hands or functional electrical stimulators (FES) to re-animate paralyzed hands. This study focuses on an ECoG-based BCI system. ECoG measures brain activity using electrodes implanted on the surface of the brain. Each participant will undergo testing of the ECoG direct brain interface for up to 29 days. Participants will learn to control computer cursors, virtual reality environments, and assistive devices such as hand orthoses and functional electrical stimulators using neural activity recorded with the ECoG sensor.

Eligibility Criteria:
Inclusion Criteria:

* Limited or no ability to use both hands due to cervical spinal cord injury, brachial plexus injury, brainstem stroke, muscular dystrophy, or amyotrophic lateral sclerosis (ALS) or other motor neuron diseases
* At least 1 year post-injury
* Live within 1 hour of the University of Pittsburgh or willing to stay in Pittsburgh while the ECoG electrode is implanted (up to 29 days)
* Additional inclusion criteria must also be reviewed

Exclusion Criteria:

* Certain implanted devices
* Presence of other serious disease or disorder that could affect ability to participate in this study
* Additional exclusion criteria must also be reviewed
CraNIRS Clinical Study

Craniosynostosis is a rare disorder characterized by a premature fusion of one or more sutures of the skull. Craniosynostosis is usually diagnosed in the first years of life. Several complications may be identified if untreated, notably, developmental delay, and vision problems.

In some patients with craniosynostosis a decrease in cerebral blood perfusion can be identified. It might be related to the constriction of the brain caused by premature sutural fusion or the localized constriction of venous sinuses.

In this study the investigator use the NIRS which is defined as a non-invasive technique to monitor hemodynamic parameters and hemoglobin oxygen saturation of the brain during the surgical correction of the craniosynostosis. By applying this method the investigator will be able to analyse the changes in cerebral hemoglobin oxygen saturation related to the modification of the skull.

Determining changes in brain oxygen saturation by using NIRS before, during and after surgery will help both to better understanding the impact of surgical decompression on improving cerebral oxygenation and to better adapt anaesthesia strategies during surgery.


Eligibility Criteria:
Inclusion Criteria:

* Boys and girls.
* Aged 3 to 18 months old.
* Subjects with a craniosynostosis diagnosis confirmed by imaging.
* Craniosynostosis requiring a corrective surgery in ventral position.
* Parents/ legal guardian must provide non opposition prior to participation in the study.

Exclusion Criteria:

- Craniosynostosis planned to be corrected by an endoscopic craniectomy or in dorsal position.
ERCP Biliary Cannulation Success Using ESGE Algorithm

Papillary cannulation attempts have been shown to be an independent predictor of post-ERCP pancreatitis (PEP) when they are repeated more than 5 times or for 5 minutes or when the pancreatic duct is opacified or cannulated by using guidewire more than 1 time. In order to reduce complications, the 2016 ESGE guideline recommends a precise sequence of alternative cannulation techniques to the primary guidewire approach before exceeding the stated limits. However, there are no published data about the routinary application of this biliary cannulation algorithm.

The investigators hypothesised that the ESGE algorithm predicts an increased cannulation success. Nevertheless, it's unclear if this benefit is also associated with a decreased risk of complications, mainly post-procedural pancreatitis.

Multicenter prospective observational study, which was promoted by SIED (the Italian Society of Digestive Endoscopy) involving Italian Centers that perform ERCP.

The study was approved from the Ethics Committee in 2020 with an expected enrollment of 800 patients over three years, with the potential to enroll patients for an extended period of time.

Each Center have to enroll a minimum of 15 consecutive patients, depending on the number of enrolling centers.

Each patient need to undergo ERCP by using the different cannulation techniques reported in the ESGE algorithm, which are numbered from 1 (easy cannulation) to 9 (difficult cannulation).

Digital data entry (RedCap application) are divided in three part: 1. before ERCP (patient demographics, indications for ERCP, the degree of anesthetic risk (ASA 1-3), any prophylactic therapy for pancreatitis, any assumption/interruption of anti-platelet and/or anti-coagulant drugs, the type of sedation); 2. ERCP (cannulation details according to ESGE algorithm, difficulty and duration of the procedure, final diagnosis, expertise of the endoscopist); 3. After ERCP (early and at 30-days complications, defined and graded according to the Cotton classification).

Eligibility Criteria:
Inclusion criteria:

* patients \> 18 years of age;
* native papilla;
* signed Informed Consent;

Exclusion criteria:

* previous biliary sphincterotomy;
* post-surgical ERCP;
* ampulloma or papilla involved by a tumor;
* pancreatic endotherapy;
* patients unable to give consent for the procedure;
Testing an Evidence-Based Program for Clinician Burnout

The goal of this clinical trial is to pilot test an app-based mindfulness training program in reducing burnout in physicians and nurses.

The main question\[s\] it aims to answer are:

PRIMARY AIM: Determine if the app-based training reduces the level of cynicism (i.e., one of the two main dimensions of burnout).

SECONDARY AIM: Determine if the app-based training reduces the level of emotional exhaustion (i.e. one of the two main dimensions of burnout), anxiety, worry, depression and intolerance of uncertainty. Determine if the app-based training increases self-compassion, non-reactivity and non-judging about inner experiences.

Participants will be asked to:

* Use an app-based mindfulness training program
* Complete online surveys at baseline, immediately post-intervention and 1 month after the post-intervention as follow up

Eligibility Criteria:
Inclusion Criteria:

* Being a physician, resident physician or nurse
* Able to speak English because all study activities will be conducted in English.
* 18+ years
* direct patient care

Exclusion Criteria:

* If using psychotropic medication - not on a stable dosage at least 6 weeks
Pulmonary Blood Flow Measurements in CHF Patients

Historically, transthoracic Doppler echocardiography has been unable to provide interpretable data of blood flow within the lung parenchyma because of air attenuation of Doppler signals. Recently, a transthoracic Doppler system known as the Sonara/tek Transcranial Doppler (TCD) System has been developed that can identify parenchymal pulmonary blood flow (PPBF) signals. The ability to non-invasively collect information regarding the pulmonary aspect of the cardio-pulmonary system may provide valuable information and new insights into the structural and functional characteristics of the lung parenchyma and vasculature in health and disease states.

This new system was previously studied among 31 healthy volunteers and one subject with atrial fibrillation.1 Pulsed spectral Doppler signals were obtained over the chest wall using a signal processing and algorithm package in conjunction with a non-imaging Doppler device coupled with an electrocardiogram. Clear reproducible lung Doppler signals (LDS) originating from different elements and phases of cardiac activity that generate mechanical waves which propagate throughout the lung were expressed in pulsatile changes in ultrasound reflections.

After the completion of the first 25 patients in our pilot study, we have received some valuable information. After assessing patients with CHF and pulmonary hypertension, we identified signals particular to the CHF group. There were unique features that were never observed in the normal patients. On top of the regular Lung Doppler signals seen in normal patients, high velocity "disorganized" variable signals that were not synchronous with the heart beat, but rather sometimes with respiration were observed. We believe that the signals may represent popping open of small bronchi surrounded by "water filled" parenchyma. These events that generate very strong reflector like signals may represent the movement of fluid at the blood vessel-alveolar air junction.

Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria

  1. Age over 50 years
  2. Belongs to one of the following categories:

     A. Decompensated CHF: patients with overt pulmonary congestion or pulmonary edema on admission, evident both clinically and by chest x-ray. Patients may be with or without a Swan-Ganz catheter.

     B. Compensated CHF: patients with significant CHF (NYHA II-IV) who are well controlled and without evidence of pulmonary congestion or pulmonary edema on admission.

     C. Non-CHF controls: patients without CHF and without any of the following: pulmonary hypertension, any known pulmonary disease, uncontrolled hypertension.
  3. Signed Informed Consent

Exclusion Criteria:

* Chronic obstructive pulmonary disease (COPD) Asthma Interstitial lung disease Any other obstructive or restrictive lung diseases Pneumonia- currently or in the past 3 months prior to inclusion Current or past pulmonary embolism Non-cardiogenic pulmonary edema or lung injury (e.g. ARDS) Right sided pleural effusion that is not mild Severe kyphosis, scoliosis or chest wall deformity
p450 Mediated Lung Toxicity

The purpose of this project is to do cross species comparisons of the metabolism and toxicity of a number of toxicants which require metabolism for toxicity. All of the toxicants in question are encountered by humans in the workplace, through lifestyle choices (cigarette smoking) and as a result of environmental contamination. The high incidence of pulmonary diseases in the human population means that it will be difficult if not impossible to determine whether humans are at risk from exposure to these chemicals without solid mechanistic data. Recent rodent bioassays suggest that these compounds have oncogenic potential further supporting the need to test the potential for injury in primates. As part of this testing, we intend to establish in vitro methods for assessing critical steps in the metabolism of these agents and their interaction with cellular macromolecules. Once this is done, similar studies can be conducted in Rhesus or in human lung tissue that is available because it cannot be used for transplant purposes.


Eligibility Criteria:
All available organ donors in the Sacramento area
A Safety Study of LY3372689 in Healthy Participants

This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3372689 or placebo and will remain in the study for up to eight weeks.


Eligibility Criteria:
Inclusion Criteria:

* Overtly healthy vasectomized male or a female who cannot get pregnant
* Have a body mass index (BMI) of 18.5 to ≤30 kilograms per square meter (kg/m²)
* Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
* Have veins suitable for ease of blood sampling

Exclusion Criteria:

* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
* Have previously participated or withdrawn from this study
* Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
* Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study